Revision 03: ใช้เฉพาะผู้ที่ข้อมูลครบในทุกตัวแปรของ Table 1; สร้างโรคร่วมใหม่จาก OPD/IPD โดยรวมประวัติหลังปี 2018 แล้ว ใช้สี่ภาค และคำนวณ annual prevalence พร้อม 95% CI ใหม่หลังคัดข้อมูลขาด
Before complete-case selection, 5,022,524 unique people met the prevalence eligibility criteria during 2017 to 30 September 2025 and 4,205,887 met at least one annual incidence risk-set criterion during 2019 to 30 September 2025. After excluding people missing any Table 1 characteristic at their first eligible entry into the respective analysis, the populations comprised 4,676,861 and 3,977,599 people, respectively. Among the retained prevalence population, 349,604 (7.48%) had H36-defined DR status in at least one eligible year. Table 1 describes the two populations separately. Recorded DR status was carried forward for annual prevalence. The incidence analysis used rolling two-year H36-free look-back windows and established recorded diabetes before each window; it is a separate analysis population. Comorbidity history was rebuilt from available OPD/IPD records from 2015 until the day before each person's entry. No qualifying code in that look-back was classified as No. Annual prevalence is reported with pointwise 95% Wilson confidence intervals. The 2025 results cover January to September only.
| Characteristic | Prevalence, 2017-Sep 2025 N=4,676,861 | Incidence, 2019-Sep 2025 N=3,977,599 |
|---|---|---|
| Analysis population | ||
| Unique people | 4,676,861 (100.00) | 3,977,599 (100.00) |
| Sex | ||
| Male | 1,840,547 (39.35) | 1,522,587 (38.28) |
| Female | 2,836,314 (60.65) | 2,455,012 (61.72) |
| Age at cohort entry, years | ||
| <18 | 17,065 (0.36) | 10,532 (0.26) |
| 18-39 | 319,538 (6.83) | 187,591 (4.72) |
| 40-49 | 766,275 (16.38) | 502,587 (12.64) |
| 50-59 | 1,452,787 (31.06) | 1,128,810 (28.38) |
| 60-69 | 1,300,549 (27.81) | 1,221,407 (30.71) |
| 70-79 | 612,996 (13.11) | 659,828 (16.59) |
| 80+ | 207,651 (4.44) | 266,844 (6.71) |
| Geographic region of linked facility | ||
| North | 947,306 (20.26) | 811,123 (20.39) |
| Northeast | 1,736,504 (37.13) | 1,476,771 (37.13) |
| Central | 1,394,478 (29.82) | 1,181,233 (29.70) |
| South | 598,573 (12.80) | 508,472 (12.78) |
| Facility type | ||
| Regional / general hospital | 1,066,746 (22.81) | 880,802 (22.14) |
| Community hospital | 1,755,766 (37.54) | 1,451,215 (36.48) |
| Primary / community health facility | 1,615,156 (34.54) | 1,455,161 (36.58) |
| Other public / non-MOPH hospital | 178,702 (3.82) | 140,729 (3.54) |
| Private hospital / clinic | 59,562 (1.27) | 48,866 (1.23) |
| Other facility | 929 (0.02) | 826 (0.02) |
| Time since first recorded diabetes at entry | ||
| <1 year | 2,291,373 (48.99) | 0 (0.00) |
| 1-<5 years | 1,052,785 (22.51) | 2,131,165 (53.58) |
| 5-<10 years | 893,077 (19.10) | 1,148,082 (28.86) |
| 10+ years | 439,626 (9.40) | 698,352 (17.56) |
| Hypertension | ||
| Yes | 1,933,087 (41.33) | 2,298,478 (57.79) |
| No | 2,743,774 (58.67) | 1,679,121 (42.21) |
| Dyslipidaemia | ||
| Yes | 1,278,714 (27.34) | 1,872,880 (47.09) |
| No | 3,398,147 (72.66) | 2,104,719 (52.91) |
| CKD / recorded diabetic renal complications | ||
| Yes | 440,057 (9.41) | 791,991 (19.91) |
| No | 4,236,804 (90.59) | 3,185,608 (80.09) |
| Ischaemic heart disease | ||
| Yes | 117,071 (2.50) | 166,113 (4.18) |
| No | 4,559,790 (97.50) | 3,811,486 (95.82) |
| Stroke / specified sequelae | ||
| Yes | 138,687 (2.97) | 202,454 (5.09) |
| No | 4,538,174 (97.03) | 3,775,145 (94.91) |
| Heart failure (I50) | ||
| Yes | 65,869 (1.41) | 114,719 (2.88) |
| No | 4,610,992 (98.59) | 3,862,880 (97.12) |
Values are n (column %). Each person is counted once within each analysis population. Age and recorded diabetes duration are assessed at first eligible entry into the respective analysis. People missing any reported characteristic are excluded from that analysis population; age below 18 is retained when known. The two populations overlap but need not be nested because their entry dates and completeness assessments differ.
Comorbidities use qualifying diagnosis codes recorded from 1 January 2015 until the day before individual entry. A person entering on 1 January 2019 therefore has the 2015-2018 look-back. Look-back length varies with entry date, so these proportions should not be read as directly comparable clinical risks between the two populations. No qualifying code is coded No under the operational study definition; it does not prove clinical absence. All extended 2019-Sep2025 extracts must complete before absence is coded No. The renal category includes recorded diabetic renal complications and is not an eGFR-confirmed CKD classification.
Region is based on the province of the linked first-recorded-diabetes facility, not residence. Study groupings comprise North (17 provinces), Northeast (20), Central (26, including Bangkok and eastern/western provinces), and South (14); the province crosswalk is retained. Facility categories reflect the supplied reference snapshot.
| Year | Eligible DM | Recorded DR status | Prevalence (%) | 95% CI (%) |
|---|---|---|---|---|
| 2017 | 2,922,455 | 87,526 | 2.99 | 2.98-3.01 |
| 2018 | 3,126,980 | 129,110 | 4.13 | 4.11-4.15 |
| 2019 | 3,290,350 | 161,611 | 4.91 | 4.89-4.94 |
| 2020 | 3,439,712 | 185,036 | 5.38 | 5.36-5.40 |
| 2021 | 3,579,151 | 200,612 | 5.61 | 5.58-5.63 |
| 2022 | 3,730,059 | 221,016 | 5.93 | 5.90-5.95 |
| 2023 | 3,904,513 | 249,643 | 6.39 | 6.37-6.42 |
| 2024 | 4,053,798 | 280,227 | 6.91 | 6.89-6.94 |
| 2025* | 4,151,969 | 303,021 | 7.30 | 7.27-7.32 |
DR is H36 in any diagnosis position. Recorded status is carried forward from the first H36 within the 2017-Sep2025 study window. Annual denominators comprise retained complete cases with diabetes recorded by period end and no recorded death by that end. Prior H36 before recorded DM is not automatically excluded. * 2025 ends 30 September. Eligibility uses recorded death because disenrollment dates are unavailable.
Pointwise 95% Wilson binomial intervals describe model-based precision of each recorded proportion. They do not cover under-recording, incomplete historical coverage, selection from complete-case exclusions, or repeated-person correlation across years. The dashed final segment identifies the shorter 2025 observation window.
Crude period recorded DR prevalence, 2017-30 September 2025, in the same complete-case prevalence population as Table 1. Each category uses its own DM denominator; H36 status and eligibility follow the period-prevalence definition. The dashed vertical line marks overall prevalence. Characteristics are assessed at first eligible entry. These proportions are unadjusted for other characteristics and observation length; the intervals are pointwise 95% Wilson CIs.
Crude period recorded DR prevalence, 2017-30 September 2025, in the same complete-case prevalence population as Table 1. Each category uses its own DM denominator; H36 status and eligibility follow the period-prevalence definition. The dashed vertical line marks overall prevalence. Characteristics are assessed at first eligible entry. These proportions are unadjusted for other characteristics and observation length; the intervals are pointwise 95% Wilson CIs.
The map uses the same crude period prevalence estimates for 2017-30 September 2025 as the regional forest plot. Province boundaries are shown for orientation; colours represent regional estimates based on linked facility province, not residence. Areas without represented patients are grey and are not assigned zero prevalence. Only four regional estimates and the overall estimate are reported; there is no separate Bangkok estimate.
| DR status carry-forward rule | DR cases (n) | DM population (n) | Prevalence (%) |
|---|---|---|---|
| Primary: until disenrollment | xxx | xxx | xxx |
| 1 year | xxx | xxx | xxx |
| 2 years | xxx | xxx | xxx |
| 3 years | xxx | xxx | xxx |
| 4 years | xxx | xxx | xxx |
| 5 years | xxx | xxx | xxx |
หมายเหตุ: ตารางนี้เป็นโครงร่างและยังไม่ได้วิเคราะห์ ไม่แนะนำให้วิเคราะห์ในรูปแบบนี้โดยตรง เนื่องจากการไม่มี H36 ซ้ำอาจเกิดจากการไม่มาตรวจตาหรือไม่ได้ลงรหัสระหว่างรับบริการอื่น การกำหนดให้สถานะหมดอายุจึงอาจสะท้อนรูปแบบบริการและการลงรหัส มากกว่าสถานะ DR จริง
| Year | Eligible population at start of year, n |
Recorded DR events, n | Person-years | Incidence proportion, % (95% CI) |
Incidence rate per 1,000 person-years (95% CI) |
|---|---|---|---|---|---|
| 2019 | 2,505,783 | 30,133 | 2,453,377.2 | 1.20 (1.19–1.22) | 12.28 (12.14–12.42) |
| 2020 | 2,702,912 | 25,094 | 2,663,975.3 | 0.93 (0.92–0.94) | 9.42 (9.30–9.54) |
| 2021 | 2,895,041 | 21,348 | 2,846,619.4 | 0.74 (0.73–0.75) | 7.50 (7.40–7.60) |
| 2022 | 3,062,550 | 27,661 | 3,007,022.5 | 0.90 (0.89–0.91) | 9.20 (9.09–9.31) |
| 2023 | 3,195,234 | 36,260 | 3,136,003.2 | 1.13 (1.12–1.15) | 11.56 (11.44–11.68) |
| 2024 | 3,316,631 | 37,608 | 3,268,203.5 | 1.13 (1.12–1.15) | 11.51 (11.39–11.62) |
| 2025* | 3,464,771 | 25,508 | 2,569,762.3 | 0.74 (0.73–0.75) | 9.93 (9.80–10.05) |
Eligibility is assessed at 1 January of each year: recorded diabetes before the two-calendar-year look-back window, no recorded death before year start, and no H36 in that window, within the retained complete-case incidence population. Events are the first H36 in the index year after this code-free window, in any diagnosis position. Earlier H36 outside the window does not exclude re-entry; events therefore need not represent first-ever DR or biological onset. Each person contributes at most one event per year, and people may appear in multiple years; annual denominators must not be summed as unique people.
Incidence proportion = events / eligible population at year start × 100, with two-sided 95% Wilson score intervals; this is a crude observed proportion, not a survival-based risk estimate. Incidence rate = events / person-years × 1,000, with two-sided exact Poisson (Garwood) intervals. Follow-up runs from 1 January to the earliest qualifying H36, recorded death, or period end; elapsed days are divided by 365.25. Death on the event date is treated as an event. Disenrollment dates are unavailable; recorded history does not establish continuous observation.
* 2025 covers 1 January–30 September only. Its proportion is not directly comparable with a full-year proportion. Person-time adjusts for differing follow-up length but not seasonality, service use or incomplete recording. Intervals are pointwise model-based precision estimates and do not account for coding/selection bias or dependence between annual estimates. No formal trend test is presented.
The dashed final segment and shaded area identify partial-year 2025. The two panels use separate units and vertical scales; confidence intervals may appear narrow because the denominators are large.
The analysis estimates associations between baseline characteristics and the cumulative incidence of first recorded DR after cohort entry, with death before DR as a competing event. It includes 3,846,216 people, 169,282 DR events, 391,162 competing deaths, and 3,285,772 administrative censored observations. Observed follow-up to first event or administrative end totals 19,409,385.3 person-years. This cohort is distinct from the annual rolling-window incidence risk sets in Table 4.
| Element | Operational definition and analysis principle |
|---|---|
| Entry and population | Use the retained complete-case incidence population. Each person enters once, at the first eligible 1 January in 2019–2025, with recorded DM before the start of the preceding two full calendar years. Entry is time zero. Eligibility uses information available through entry; persons do not re-enter after an event. |
| Prior DR exclusion | Exclude H36 in any diagnosis position anywhere in the available history through and including entry day, even if older than two years. All available OPD/IPD H36 sources are searched; the earliest observed record is 16 October 2014, without assuming complete uniform coverage back to that date. Excluded: 124,522 people with prior/same-day H36 and another 6,861 with recorded death on/before entry. |
| DM duration | Baseline recorded DM duration = (entry date − first recorded DM diagnosis date)/365.25. The DM date is the earliest parseable CHRONIC E10–E14 date_diag, not verified biological onset. Adjust using 1–<5, 5–<10 and ≥10 years; 1–<5 is reference. The history requirement leaves no <1-year group. |
| Event coding | Status 1: first H36 strictly after entry, no later than recorded death and no later than 30 September 2025. Status 2: death before qualifying DR. Status 0: administrative end without either event. One DR event maximum per person. This is first recorded DR among those without a detected prior code, not proven first-ever disease onset. |
| Dates and observation | Observed follow-up ends at the earliest DR, death or 30 September 2025. Elapsed days are used in computation; years = days/365.25. Same-day DR/death is assigned DR (9 people). Year–month-only death dates follow the existing first-day-of-month convention, so ordering is approximate. Disenrollment and validated loss-to-follow-up dates are unavailable. |
| Baseline factors | Mutually adjust sex, age group, linked-facility region/type, recorded DM duration, hypertension, dyslipidaemia, CKD/recorded diabetic renal complications, ischaemic heart disease, stroke/specified sequelae and heart failure. Factors are fixed at entry. Comorbidities use qualifying codes from 1 January 2015 strictly before entry; no qualifying code = No under the operational definition. Region is facility province, not residence. |
| Fine–Gray model | Fit a proportional subdistribution-hazards regression for DR with death as the competing event. Estimate the censoring distribution separately within calendar-entry-year groups and stratify the baseline subdistribution hazard by entry year. Use Breslow handling of tied event days and subject-cluster robust sandwich standard errors; report adjusted subdistribution HRs (sHRs) and robust Wald 95% CIs. |
| Competing-death risk sets | Subjects who die before DR are retained in the mathematical Fine–Gray risk sets according to the model's weighting rule; they are not treated as people who can physically develop DR after death. Within each entry-year group, the only censoring is a common administrative horizon, so inverse-censoring weights are exactly one before that horizon. R finegray verifies this for every transformed row. The extended risk-set time is not reported as observed person-time. |
| Interpretation | sHR relates baseline factors to the DR cumulative incidence function in the presence of competing death. It is not an ordinary hazard ratio among survivors, a cumulative-risk ratio, or proof of a causal effect. Associations can reflect both DR recording and competing mortality. A lower estimate in an older or severely ill group does not establish protection from DR. |
| Proportionality diagnostic | Use a prespecified robust efficient-score test for factor × log(1 + follow-up years), projecting out the baseline coefficients. The subject-score sandwich and information matrices use the full Fine–Gray risk sets. The calculation is independently checked against R and an explicitly time-split reference model. This tests a particular time trend; it is not proof of all forms of proportionality when nonsignificant. |
| AJ estimator | Retain the unadjusted Aalen–Johansen cumulative incidence curves, with death before DR as a competing event. Update F_DR(t)=F_DR(t−)+S(t−)d_DR(t)/Y(t), with S based on both first-event types. Use the common pre-event risk set for ties and censor after events. Pointwise 95% log-log CIs use validated multinomial transition-increment covariance propagation. AJ is descriptive; Fine–Gray provides covariate-adjusted associations. |
Historical code absence is not a negative retinal examination or proof of continuous enrollment. Source coverage, service use, coding, selection, referral patterns and approximate death dates affect interpretation; confidence intervals do not cover those biases. AJ curves pool entry cohorts with different administrative follow-up lengths and assume noninformative censoring within reported groups. Table 1 describes the candidate incidence population, not the final Fine–Gray cohort.
Time-varying associations: the Fine–Gray log-time diagnostic rejects proportional subdistribution hazards globally (χ²=6,387.25, df=23, p<0.001). The overall sHRs in Table 5 are follow-up summaries, not constant effects. Table 6 and Figure 6 provide interval-specific subdistribution-HR summaries for interpretation.
| Characteristic | People, n | DR events, n | Adjusted sHR (95% CI) | p-value |
|---|---|---|---|---|
| Sex | ||||
| Male | 1,478,564 | 56,210 | 1.00 (Reference) | — |
| Female | 2,367,652 | 113,072 | 1.11 (1.10–1.12) | <0.001 |
| Age at cohort entry (years) | ||||
| <18 | 10,433 | 243 | 0.47 (0.42–0.54) | <0.001 |
| 18-39 | 184,227 | 9,316 | 1.00 (Reference) | — |
| 40-49 | 490,566 | 28,843 | 0.97 (0.94–0.99) | 0.005 |
| 50-59 | 1,092,439 | 61,824 | 0.78 (0.76–0.80) | <0.001 |
| 60-69 | 1,173,919 | 50,370 | 0.49 (0.48–0.50) | <0.001 |
| 70-79 | 635,255 | 16,205 | 0.25 (0.24–0.26) | <0.001 |
| 80+ | 259,377 | 2,481 | 0.09 (0.09–0.10) | <0.001 |
| Region of linked facility | ||||
| North | 786,660 | 32,436 | 1.00 (Reference) | — |
| Northeast | 1,429,347 | 59,114 | 1.04 (1.02–1.05) | <0.001 |
| Central | 1,137,342 | 51,801 | 1.24 (1.22–1.26) | <0.001 |
| South | 492,867 | 25,931 | 1.35 (1.33–1.38) | <0.001 |
| Type of linked facility | ||||
| Regional / general hospital | 845,073 | 39,869 | 1.00 (Reference) | — |
| Community hospital | 1,406,059 | 58,479 | 0.77 (0.76–0.78) | <0.001 |
| Primary / community health facility | 1,408,344 | 66,644 | 0.83 (0.82–0.84) | <0.001 |
| Other public / non-MOPH hospital | 138,030 | 2,463 | 0.59 (0.57–0.62) | <0.001 |
| Private hospital / clinic | 47,906 | 1,760 | 0.84 (0.80–0.88) | <0.001 |
| Other facility | 804 | 67 | 1.51 (1.19–1.92) | <0.001 |
| Recorded DM duration at entry | ||||
| 1-<5 years | 2,098,698 | 59,598 | 1.00 (Reference) | — |
| 5-<10 years | 1,105,892 | 65,931 | 1.51 (1.49–1.53) | <0.001 |
| 10+ years | 641,626 | 43,753 | 1.90 (1.87–1.93) | <0.001 |
| Hypertension | ||||
| No | 1,662,396 | 54,496 | 1.00 (Reference) | — |
| Yes | 2,183,820 | 114,786 | 1.42 (1.40–1.44) | <0.001 |
| Dyslipidaemia | ||||
| No | 2,073,280 | 71,717 | 1.00 (Reference) | — |
| Yes | 1,772,936 | 97,565 | 1.42 (1.40–1.43) | <0.001 |
| CKD / recorded diabetic renal complications | ||||
| No | 3,119,939 | 126,237 | 1.00 (Reference) | — |
| Yes | 726,277 | 43,045 | 1.29 (1.28–1.31) | <0.001 |
| Ischaemic heart disease | ||||
| No | 3,693,419 | 162,162 | 1.00 (Reference) | — |
| Yes | 152,797 | 7,120 | 0.99 (0.96–1.02) | 0.412 |
| Stroke / specified sequelae | ||||
| No | 3,659,480 | 161,763 | 1.00 (Reference) | — |
| Yes | 186,736 | 7,519 | 0.93 (0.91–0.96) | <0.001 |
| Heart failure (I50) | ||||
| No | 3,745,793 | 164,682 | 1.00 (Reference) | — |
| Yes | 100,423 | 4,600 | 1.00 (0.96–1.03) | 0.808 |
References: male; age 18–39; North; regional/general hospital; recorded DM duration 1–<5 years; No for each comorbidity. Age <18 is retained and listed first for ascending age order. All factors are adjusted simultaneously. Entry-year baseline strata have no reported coefficient. Counts refer to the full single-entry cohort. Large N makes small differences statistically detectable; sHR is not a risk ratio.
| Characteristic | 0–<2 years sHR (95% CI) | 2–<4 years sHR (95% CI) | ≥4 years sHR (95% CI) |
|---|---|---|---|
| Sex | |||
| Male | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
| Female | 1.04 (1.03–1.06) | 1.09 (1.07–1.12) | 1.20 (1.18–1.23) |
| Age at cohort entry (years) | |||
| <18 | 0.50 (0.39–0.63) | 0.49 (0.39–0.63) | 0.43 (0.35–0.52) |
| 18-39 | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
| 40-49 | 1.04 (1.00–1.09) | 0.92 (0.88–0.96) | 0.94 (0.91–0.97) |
| 50-59 | 0.92 (0.88–0.96) | 0.76 (0.73–0.80) | 0.69 (0.66–0.71) |
| 60-69 | 0.68 (0.65–0.70) | 0.49 (0.47–0.51) | 0.37 (0.36–0.38) |
| 70-79 | 0.39 (0.37–0.40) | 0.25 (0.24–0.26) | 0.16 (0.16–0.17) |
| 80+ | 0.17 (0.16–0.18) | 0.09 (0.08–0.09) | 0.04 (0.04–0.05) |
| Region of linked facility | |||
| North | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
| Northeast | 1.02 (0.99–1.04) | 0.99 (0.96–1.02) | 1.10 (1.07–1.12) |
| Central | 1.23 (1.20–1.26) | 1.17 (1.14–1.20) | 1.30 (1.27–1.33) |
| South | 1.35 (1.31–1.39) | 1.27 (1.22–1.31) | 1.43 (1.39–1.47) |
| Type of linked facility | |||
| Regional / general hospital | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
| Community hospital | 0.67 (0.66–0.69) | 0.74 (0.72–0.76) | 0.93 (0.91–0.95) |
| Primary / community health facility | 0.75 (0.74–0.77) | 0.80 (0.78–0.82) | 0.94 (0.92–0.96) |
| Other public / non-MOPH hospital | 0.57 (0.53–0.61) | 0.64 (0.59–0.69) | 0.59 (0.55–0.64) |
| Private hospital / clinic | 0.77 (0.71–0.83) | 0.87 (0.79–0.95) | 0.92 (0.85–1.00) |
| Other facility | 1.63 (1.14–2.33) | 1.74 (1.14–2.68) | 1.16 (0.72–1.88) |
| Recorded DM duration at entry | |||
| 1-<5 years | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
| 5-<10 years | 1.52 (1.49–1.56) | 1.56 (1.52–1.61) | 1.48 (1.45–1.51) |
| 10+ years | 2.06 (2.01–2.11) | 1.97 (1.91–2.03) | 1.76 (1.72–1.80) |
| Hypertension | |||
| No | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
| Yes | 1.68 (1.64–1.71) | 1.38 (1.35–1.42) | 1.24 (1.22–1.27) |
| Dyslipidaemia | |||
| No | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
| Yes | 1.46 (1.43–1.49) | 1.39 (1.36–1.42) | 1.39 (1.37–1.42) |
| CKD / recorded diabetic renal complications | |||
| No | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
| Yes | 1.47 (1.44–1.50) | 1.22 (1.19–1.25) | 1.15 (1.13–1.18) |
| Ischaemic heart disease | |||
| No | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
| Yes | 1.04 (1.00–1.08) | 0.97 (0.92–1.02) | 0.91 (0.87–0.96) |
| Stroke / specified sequelae | |||
| No | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
| Yes | 1.08 (1.04–1.12) | 0.88 (0.84–0.93) | 0.74 (0.71–0.78) |
| Heart failure (I50) | |||
| No | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
| Yes | 1.27 (1.22–1.33) | 0.90 (0.84–0.96) | 0.63 (0.59–0.68) |
Separate fits use the original Fine–Gray extended risk sets within approximate two-year bands (0–730, >730–1461 and >1461 elapsed days), with the same baseline factors, entry-year strata and subject-robust standard errors. Prior competing deaths remain in the extended risk sets; these are not landmark analyses restricted to survivors. The estimates permit differences between bands but remain summaries within bands; they do not establish proportionality within each band. No formal test comparing the separate period estimates is presented.
At five years, first recorded DR cumulative incidence is 3.93% (95% CI 3.91–3.95); death before recorded DR is 10.08% (95% CI 10.05–10.11). These are unadjusted absolute cumulative incidences; sHRs do not equal ratios of these values.
| Baseline characteristic | People at entry, n | 3-year CIF, % (95% CI) | 5-year CIF, % (95% CI) |
|---|---|---|---|
| Overall | |||
| Overall | 3,846,216 | 2.36 (2.34–2.38) | 3.93 (3.91–3.95) |
| Sex | |||
| Male | 1,478,564 | 2.16 (2.14–2.19) | 3.53 (3.50–3.56) |
| Female | 2,367,652 | 2.48 (2.46–2.50) | 4.17 (4.14–4.19) |
| Age at cohort entry (years) | |||
| <18 | 10,433 | 1.07 (0.88–1.30) | 2.07 (1.78–2.39) |
| 18-39 | 184,227 | 2.44 (2.37–2.52) | 4.85 (4.74–4.97) |
| 40-49 | 490,566 | 2.87 (2.82–2.92) | 5.32 (5.25–5.40) |
| 50-59 | 1,092,439 | 2.92 (2.89–2.95) | 5.08 (5.04–5.13) |
| 60-69 | 1,173,919 | 2.47 (2.44–2.50) | 3.89 (3.85–3.93) |
| 70-79 | 635,255 | 1.57 (1.54–1.60) | 2.28 (2.24–2.32) |
| 80+ | 259,377 | 0.67 (0.63–0.70) | 0.89 (0.85–0.92) |
| Region of linked facility | |||
| North | 786,660 | 2.24 (2.21–2.27) | 3.66 (3.62–3.70) |
| Northeast | 1,429,347 | 2.19 (2.16–2.21) | 3.61 (3.58–3.65) |
| Central | 1,137,342 | 2.47 (2.44–2.50) | 4.17 (4.13–4.21) |
| South | 492,867 | 2.81 (2.76–2.85) | 4.72 (4.65–4.78) |
| Type of linked facility | |||
| Regional / general hospital | 845,073 | 2.73 (2.70–2.77) | 4.39 (4.34–4.44) |
| Community hospital | 1,406,059 | 2.18 (2.15–2.20) | 3.74 (3.71–3.78) |
| Primary / community health facility | 1,408,344 | 2.44 (2.41–2.46) | 4.01 (3.98–4.05) |
| Other public / non-MOPH hospital | 138,030 | 1.09 (1.04–1.15) | 1.84 (1.76–1.93) |
| Private hospital / clinic | 47,906 | 2.31 (2.17–2.46) | 3.85 (3.66–4.05) |
| Other facility | 804 | 5.43 (3.98–7.18) | 8.39 (6.51–10.57) |
| Recorded DM duration at entry | |||
| 1-<5 years | 2,098,698 | 1.81 (1.79–1.83) | 3.06 (3.03–3.08) |
| 5-<10 years | 1,105,892 | 2.70 (2.67–2.73) | 4.43 (4.39–4.47) |
| 10+ years | 641,626 | 3.41 (3.36–3.45) | 5.27 (5.22–5.33) |
| Hypertension | |||
| No | 1,662,396 | 1.54 (1.52–1.56) | 2.85 (2.82–2.87) |
| Yes | 2,183,820 | 2.98 (2.96–3.00) | 4.74 (4.71–4.77) |
| Dyslipidaemia | |||
| No | 2,073,280 | 1.70 (1.68–1.72) | 2.98 (2.95–3.00) |
| Yes | 1,772,936 | 3.15 (3.12–3.17) | 5.07 (5.03–5.10) |
| CKD / recorded diabetic renal complications | |||
| No | 3,119,939 | 2.10 (2.09–2.12) | 3.63 (3.60–3.65) |
| Yes | 726,277 | 3.45 (3.40–3.49) | 5.16 (5.11–5.22) |
| Ischaemic heart disease | |||
| No | 3,693,419 | 2.33 (2.31–2.35) | 3.90 (3.88–3.93) |
| Yes | 152,797 | 3.11 (3.02–3.20) | 4.46 (4.35–4.57) |
| Stroke / specified sequelae | |||
| No | 3,659,480 | 2.34 (2.32–2.35) | 3.92 (3.90–3.94) |
| Yes | 186,736 | 2.84 (2.76–2.92) | 4.08 (3.98–4.18) |
| Heart failure (I50) | |||
| No | 3,745,793 | 2.33 (2.31–2.35) | 3.91 (3.89–3.93) |
| Yes | 100,423 | 3.54 (3.42–3.66) | 4.63 (4.49–4.77) |
Pointwise CIs are not simultaneous bands. Longer-horizon estimates rely on earlier-entry cohorts still observed. The existing individual AJ graphs include numbers-at-risk tables; all AJ estimates and figures are unchanged by replacing the regression model.
Methods: Fine–Gray transformation and subject-robust inference; AJ and competing risks. Fine–Gray models were fitted using R survival 3.8.3; numerical checks independently reproduce the full-data likelihood, scores and robust covariance.